Why Your Company Needs an AI Assistant: Patient Engagement from First Contact

In an era where digital transformation is reshaping healthcare, the industry is experiencing a significant shift towards more patient-centered services. AI-based virtual assistance is at the forefront of this transformation, providing seamless, efficient, and personalized guidance at symptom onset. Its role in facilitating patient engagement is becoming increasingly indispensable for every stakeholder in the healthcare ecosystem. You can read the full article here: https://www.mediktor.com/es/news/news/why-your-company-needs-an-ai-assistant-patient-engagement-from-first-contact  

Peptomyc Appoints Selwyn Ho to its Board of Directors

Barcelona, Spain, March 21st, 2024 Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, to its Board of Directors. Giacomo Di Nepi, Chairman of Peptomyc, says: “We are delighted to have Selwyn joining us. His impressive track record in the Healthcare sector, together with his experience in different executive…

Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours.

OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble factors with the potential as pharmacodynamic and predictive response markers. https://www.nature.com/articles/s41591-024-02805-1.epdf?sharing_token=Kb6gG5E9yqkeIKGERvlDs9RgN0jAjWel9jnR3ZoTv0PbA8JGCp8lm6FKJ7Jh-32YH7J2xVsk_KGC2EJRU1fEovpCc4NhoH9mLlaGUrqCoPgvJZNKyZVnNLFM1UXLoCexi1Zxi7bZ2rOl-ZxWgZOy8orQl2v1yuum2gO9zR0Zarg%3D